From: Could local surgery improve survival in de novo stage IV breast cancer?
Characteristic | Univariable HR*(95%CI) | P | Multivariable HR*(95%CI) | P |
---|---|---|---|---|
Surgery | ||||
āYes vs No | 0.56(0.382-0.820) | 0.003 | 0.53(0.36-0.78) | 0.001 |
Viscera metastasis | ||||
āYes vs no | 1.73 (1.18-2.54) | 0.005 | Ā | |
Bone metastasis | ||||
āYes vs no | 0.91 (0.62-1.32) | 0.610 | Ā | |
CNS metastasis | ||||
āYes vs no | 1.40 (0.44-4.43) | 0.566 | Ā | |
Soft tissue metastasis | ||||
āYes vs no | 0.99 (0.68-1.46) | 0.977 | Ā | |
Age | ||||
āā¤50 vs >50 | 0.65 (0.44-0.95) | 0.026 | Ā | |
Menopause status | ||||
āMenopause vs menses | 1.21 (0.82-1.77) | 0.344 | Ā | |
Biopsy | ||||
āmass resection | 1Ā§ | 0.753 | Ā | |
ācore needle | 1.32 (0.64-2.73) | 0.457 | Ā | |
āfine needle | 1.43 (0.18-11.59) | 0.736 | Ā | |
Histology | ||||
āductal | 1Ā§ | 0.824 | Ā | |
ālobular | 0.66 (0.16-2.69) | 0.563 | Ā | |
āothers | 1.11 (0.41-3.05) | 0.835 | Ā | |
Tumor size | ||||
ā>5 cm vs ā¤5 cm | 1.00 (0.67-1.49) | 0.981 | Ā | |
Lymph node involvement | ||||
āN0 | 1Ā§ | 0.259 | Ā | |
āN1 | 2.48 (1.00-6.11) | 0.049 | Ā | |
āN2 | 1.95 (0.80-4.74) | 0.142 | Ā | |
āN3 | 2.14 (0.91-5.05) | 0.081 | Ā | |
HER2 receptor status | ||||
āAmplified | 1Ā§ | 0.557 | Ā | |
āNo-amplified | 0.81 (0.55-1.21) | 0.304 | Ā | |
āNot known or equivocal(2+) | 0.77 (0.31-1.93) | 0.574 | Ā | |
Hormone receptor status | ||||
ā+ vs - | 0.49 (0.321-0.7233) | <0.001 | 0.57 (0.36-0.89) | 0.013 |
No. of metastasis sites | ||||
ā>3 vs ā¤3 | 1.751 (0.881-3.477) | 0.11 | Ā | |
Endocrine therapy$ | ||||
āYes vs no | 0.45 (0.30-0.68) | <0.001 | 0.55 (0.35-0.86) | 0.009 |
Anti-HER2 therapy$ | ||||
āNo | 1Ā§ | 0.11 | Ā | |
āYes | 0.54 (0.325-1.008) | 0.035 | Ā | |
āUnknown | 0.00 (0.00-5.357E+159) | 0.959 | Ā | |
Radiotherapy | ||||
āNo | 1Ā§ | 0.029 | Ā | |
āYes | 0.61 (0.40-0.94) | 0.025 | Ā | |
āUnknown | 1.35 (0.71-2.57) | 0.357 | Ā |